Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 10;23(2):128. doi: 10.3892/mmr.2020.11767

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhao et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 6. — Sensitivity to cisplatin in different treatment groups. (A) The proliferation inhibition rate was higher in the GANT61 group than in the SHH and control groups, and the IC₅₀ decreased from 3.151±0.289 to 0.517±0.022 µg/ml after GANT61 treatment for 24 h. (B) The proliferation inhibition rate was higher in the GANT61 group than in the SHH and control groups, and the IC₅₀ decreased from 1.121±0.050 to 0.050±0.012 µg/ml after GANT61 treatment for 48 h. (C) The proliferation inhibition rate was higher in the GANT61 group than in the SHH and control groups, and the IC₅₀ decreased from 0.368±0.102 to 0.073±0.012 µg/ml after GANT61 treatment for 72 h. (D) The IC₅₀ of cisplatin against SKOV3 cells in response to different treatments groups. *P<0.05 vs. control; ^##P>0.05 vs. control. SHH, recombinant human sonic HH.